Clinical trial
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors
NCT04660929 is registered in ClinicalTrials.gov with Carisma Therapeutics Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors
- Lead sponsor
- Carisma Therapeutics Inc
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- February 2, 2021
- Completion date
- December 31, 2024
- Enrollment
- 48 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, bile duct cancer, biliary tract cancer, bladder cancer, breast cancer, breast neoplasm, cancer, carcinoma, ductal, carcinoma, hepatocellular, carcinoma, ovarian epithelial, carcinoma, small cell, carcinoma, squamous, carcinoma, transitional cell, colorectal cancer, endometrial cancer, esophagogastric junction neoplasms, head and neck cancer, her-2 gene amplification, her-2 protein overexpression, her2-positive, her2-positive breast cancer, her2-positive gastric cancer, her2-positive solid tumors, inflammatory breast cancer, lung cancer, non-small-cell, lung cancer, small cell, malignant neoplasms, ovarian neoplasms, pancreatic cancer, prostate cancer, stomach neoplasms